Role of ADAMTS (A Disintegrin and Metalloproteinase With Thrombospondin Motifs)-5 in Aortic Dilatation and Extracellular Matrix Remodeling. by Fava, M et al.
1ECM (extracellular matrix) degradation and remodeling is a hallmark of aortic aneurysm formation. The precise 
mechanisms behind the degradation of ECM components and 
subsequent dissection of the vessel wall are not completely 
elucidated. Histologically, diseased aortas present with vari-
able degrees of ECM degeneration within the aortic medial 
layer, including cystic medial degeneration, elastic fiber frag-
mentation, and myxomatous degeneration. At the molecular 
level, aortic degeneration has been associated with vascular 
smooth muscle cell (SMC) apoptosis1 and inflammation.2 
Factors that contribute to aortic wall degeneration both in 
humans and in animal models include AngII (angiotensin II),3 
TGF-β transforming growth factor-β),4 and MMPs (matrix 
metalloproteinases).5 The role of MMPs in the alteration of 
aortic ECM architecture has been extensively studied in the 
context of aortic aneurysm development.5,6 More recently, 
a family of metalloproteases known as ADAMTSs (a dis-
integrin and metalloprotease with thrombospondin motifs) 
has been explored in vascular ECM turnover. In particular, 
ADAMTS-1, -4, and -5 activities have been implicated in tho-
racic aortic aneurysm (TAA) formation.3,7,8
ADAMTS-1, -4, and -5 are the main enzymes responsible 
for large aggregating proteoglycan cleavage.9,10 We have pre-
viously demonstrated that ADAMTS-5 is reduced in aortas 
of apolipoprotein E–null mice and that ADAMTS-5 activ-
ity affects proteoglycan-mediated lipoprotein retention.11 
We have also shown that on stent-induced vascular injury, a 
reduction in ADAMTS-1 and ADAMTS-5 contributes to an 
increase in large aggregating proteoglycans, notably aggrecan 
and versican.12 Similarly, the absence of ADAMTS-5 leads to 
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Objective—Thoracic aortic aneurysm (TAA), a degenerative disease of the aortic wall, is accompanied by changes in the 
structure and composition of the aortic ECM (extracellular matrix). The ADAMTS (a disintegrin and metalloproteinase 
with thrombospondin motifs) family of proteases has recently been implicated in TAA formation. This study aimed to 
investigate the contribution of ADAMTS-5 to TAA development.
Approach and Results—A model of aortic dilatation by AngII (angiotensin II) infusion was adopted in mice lacking the 
catalytic domain of ADAMTS-5 (Adamts5Δcat). Adamts5Δcat mice showed an attenuated rise in blood pressure while 
displaying increased dilatation of the ascending aorta (AsAo). Interestingly, a comparison of the aortic ECM from AngII-
treated wild-type and Adamts5Δcat mice revealed versican as the most upregulated ECM protein in Adamts5Δcat mice. This 
was accompanied by a marked reduction of ADAMTS-specific versican cleavage products (versikine) and a decrease 
of LRP1 (low-density lipoprotein-related protein 1). Silencing LRP1 expression in human aortic smooth muscle cells 
reduced the expression of ADAMTS5, attenuated the generation of versikine, but increased soluble ADAMTS-1. A similar 
increase in ADAMTS-1 was observed in aortas of AngII-treated Adamts5Δcat mice but was not sufficient to maintain 
versican processing and prevent aortic dilatation.
Conclusions—Our results support the emerging role of ADAMTS proteases in TAA. ADAMTS-5 rather than ADAMTS-1 is 
the key protease for versican regulation in murine aortas. Further studies are needed to define the ECM substrates of the 
different ADAMTS proteases and their contribution to TAA formation.  (Arterioscler Thromb Vasc Biol. 2018;38:00-00. 
DOI: 10.1161/ATVBAHA.117.310562.)
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2  Arterioscler Thromb Vasc Biol  June 2018
the developmental defects including myxomatous valve mal-
formation. Mice lacking ADAMTS-5 activity cannot degrade 
versican during the remodeling of the valve cushion resulting 
in enlarged pulmonary and aortic valve cusps.13 LRP1 (low-
density lipoprotein-related protein 1), a widely expressed 
receptor, is known to mediate ADAMTS-5 clearance by 
promoting its endocytosis. Interestingly, LRP1 has been 
implicated in aneurysm formation; LRP1 deletion in SMCs 
profoundly augmented AsAo aneurysm formation induced by 
AngII.14
In the present article, we aim to characterize regional 
differences in ADAMTS expression in murine aortas and to 
explore aortic ECM changes in mice with loss of ADAMTS-5 
activity. Because the ECM is an intricate protein network 
and alterations in proteolytic activity will induce secondary 
remodeling processes, we used our established proteomics 
approach for studying the vascular ECM.15
Materials and Methods
An expanded Materials and Methods section is available in the online-
only Data Supplement. The data that support the findings of this study 
are available from the corresponding author on reasonable request.
Animal Experiments
All animal procedures were performed by authorized researchers 
in the Cardiovascular Division, King’s College London. Housing 
and animal care was in accordance with the UK Animals (Scientific 
Procedures) Act 1986. Genotyping of Adamts5Δcat and control 
(Adamts5+/+) mice was performed as previously published.11 For 
AngII infusion, osmotic mini-pumps (Alzet, model 1004) contain-
ing AngII (1.44 mg g−1 d−1 dissolved in saline) were implanted in 
10- to 12-week-old male Adamts5Δcat and Adamts5+/+ mice derived 
from littermates of heterozygous breeders (JAX stock no. 005771, 
B6.129P2-Adamts5tm1Dgen/J). Animals were euthanized after 4 weeks, 
and the entire aorta was excised and immediately washed in ster-
ile PBS. The entire aorta was snap-frozen at −80°C for subsequent 
proteomic analysis. For gene expression analysis, aortic tissue was 
divided into anatomically defined regions using a scalpel under a dis-
secting microscope, followed by immediate storage at −80°C. Aortic 
diameter was monitored using ultrasound at day 0 (baseline) and after 
27 days of AngII treatment using Vevo software version 1.7.
Mouse Echocardiography
Animals were anesthetized using 5% isoflurane mixed with 1 L/min 
of 100% oxygen for 45 seconds to 1 minute. Mice were then placed 
in a supine position on a heating pad with embedded ECG registra-
tion. On adequate induction, 1% to 1.5% isoflurane mixed with 1 L/
min 100% oxygen was used to maintain a steady state of sedation 
throughout the procedure. A rectal probe was inserted to continu-
ously monitor the body temperature. Electrode gel was applied to the 
4 paws, which were taped to the ECG electrodes. Two-dimensional 
echocardiographic images of cardiovascular anatomy were obtained 
by a single operator. Standard and modified parasternal long-axis, 
suprasternal, longitudinal abdominal, and transverse abdominal views 
were obtained using Visual Sonics Vevo 2100. Aortic root dimensions 
(aortic annulus, sinuses of Valsalva, and sinotubular junction) were 
measured in parasternal long-axis view. AsAo dimensions were mea-
sured during systole and diastole in suprasternal view where possible 
and modified parasternal long-axis view if suprasternal views were 
considered inadequate. Measurements were taken from leading edge-
to-leading edge. Abdominal aorta measurements were made in the 
TA view. All measurements were performed offline (Vevo software 
version 1.7) by 2 consensus interpreters.
Blood Pressure Monitoring
The blood pressure was directly measured via an implantable radio-
telemetry device. An average of 200 values were acquired every 5 
minutes for 18 to 20 hours. Blood pressure was monitored using 
telemetry probes 2 days before mini-pump implantation and at days 5 
and 27 of AngII infusion.
ECM Protein Extraction From Murine Aortas
Aortic samples were partially thawed and diced into smaller pieces to 
aid the removal of plasma contaminants and for the effective extrac-
tion of ECM proteins.16,17 ECM protein enrichment of aortic samples 
was performed using an adaptation of our previously published 3-step 
extraction method, involving sequential incubation with 0.5 mol/L 
NaCl for 2 hours, 0.08% sodium dodecyl sulfate (SDS) for 2 hours, 
and a final incubation with 4 mol/L guanidine hydrochloride (GuHCl) 
for 48 hours. After precipitation of GuHCl extracts, protein samples 
were enzymatically deglycosylated and subjected to in-solution tryp-
sin digestion. Details are given in Online Methods in the online-only 
Data Supplement.
Proteomics Analysis of ECM Extracts
After deglycosylation (protocol details are provided in the Online 
Methods in the online-only Data Supplement), digested peptides 
were separated on a nanoflow liquid chromatography system, and 
GuHCl extracts were injected for liquid chromatography-tandem 
mass spectrometry analysis into a Q Exactive HF mass spectrometer 
(Thermo Fisher Scientific) for discovery proteomics. Acquisition was 
performed as previously described.15 For targeted MS analysis, an 
isolation list was created for proteotypic peptides of mouse versican 
and GuHCl extracts were analyzed via parallel reaction monitoring 
mode on a Q Exactive HF mass spectrometer. Details are given in 
Online Methods in the online-only Data Supplement.
Total Protein Extraction From Murine Aortas
Mouse aortic samples were homogenized in the presence of 300 μL 
of tissue lysis buffer (0.152 g of Tris, 0.33 g of NaCl, 0.038 g of 
EGTA, 0.073 g of EDTA, 500 μL of Triton, and 250 μL of 20% SDS) 
at pH 7.4. Protein concentration was measured using BCA protein 
assay kit, and Western blots were performed following the protocol in 
the Online Methods in the online-only Data Supplement.
Cell Culture of Human Arterial SMCs
Samples of internal mammary artery were collected from patients 
undergoing bypass graft surgery at Leeds General Infirmary, con-
forming with the principles outlined in the Declaration of Helsinki. 
Nonstandard Abbreviations and Acronyms
ADAMTS a disintegrin and metalloproteinase with thrombospondin 
motifs
AngII angiotensin II
AsAo ascending aorta
CO6A6 collagen type VI α-6
COCA1 collagen type XII α-1
ECM extracellular matrix
FINC fibronectin
GuHCl guanidine hydrochloride
LRP1 low-density lipoprotein-related protein 1
MFAP5 microfibrillar-associated protein 5
MMPs matrix metalloproteinases
SDS sodium dodecyl sulfate
SMCs smooth muscle cells
TAA thoracic aortic aneurysm
TGF-β transforming growth factor-β
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Arterial SMCs were extracted and expanded using an explant tech-
nique.18 SMCs were seeded into 6-well tissue culture plates. Twenty-
four hours after seeding, cells were cultured in serum-free DMEM 
for 1 hour. Ten nanogram per milliliter of human TGF-β1 (R&D sys-
tems) was diluted in serum-free DMEM (1195-045; Gibco), and cells 
were treated for 24 hours. Changes in versican expression after stimu-
lation were measured by real-time quantitative PCR using TaqMan 
assay for the corresponding human target. Major Resources Table is 
given in the online-only Data Supplement.
Quantitative Real-Time PCR
RNA extraction was performed using the miRNeasy Mini Kit (Qiagen) 
following the manufacturers’ protocol. RNA concentration (Abs 260 
nm) and purity (260/280) were measured in 1 μL of eluted RNA 
using spectrophotometry (NanoDrop ND-1000; Thermo Scientific). 
RNA integrity was evaluated using the Agilent Bioanalyzer System 
and considered acceptable if the RNA integrity number was >7. The 
RNA was then reverse transcribed using random hexamers with 
SuperScript VILO MasterMix (Invitrogen) according to manufactur-
ers’ protocol, with sample preparation being performed on a StarChill 
PCR rack to maintain low temperature. The reverse transcription 
product was diluted 1:15 to 1:25 using RNase-free water. TaqMan 
hydrolysis probes were used for quantitative PCR analysis. Data were 
analyzed using ViiA 7 software (Applied Biosystems). A minimum 
of 2 reference genes was used throughout the study, and stability 
of RNA isolation, reverse transcription, and quantitative PCR was 
determined by variability of and correlation between reference genes. 
Analysis of stability was also performed using geNorm, a commonly 
used algorithm for validation of reference gene stability based on the 
comparative cycle-to-threshold method.19 Relative amounts of the tar-
gets were calculated using the 2−∆∆Cq method,20 with statistical analy-
sis performed on ∆Cq values.
Immunofluorescence Staining in Murine AsAo
Murine aortas were fixed for 24 hours in 4% formaldehyde at room 
temperature. In brief, 3-μm sections were deparaffinized in xylene 
and rehydrated in graded ethanol. The slides were unmasked using 
hot sodium citrate buffer (pH 6.0), then permeabilized for 20 min-
utes in 0.1% Triton X-100. Sections were blocked with 10% serum at 
room temperature, before incubation with primary antibodies against 
LRP1 and α–smooth muscle actin or species-matched isotopes over-
night at 4°C. After washes in PBST, sections were incubated for 1 
hour at room temperature with the secondary antibody. Nuclei were 
stained using DAPI for 10 minutes. Sections were visualized under a 
Nikon spinning disk confocal microscope (KO.18), and images were 
acquired using NIS-elements 4.0 software. Scale bars are included in 
the images as indicated in the figure legends.
Transfection Experiments in Human Aortic SMCs
Human aortic SMCs were purchased from LONZA and cul-
tured in SMC medium (cc-3183; LONZA) with 5% fetal bovine 
serum (LONZA). SMCs were seeded into 6-well tissue cul-
ture plates, and 24 hours after seeding, cells were transfected 
with 50 nmol/L of LRP1 siRNA (Dharmacon, M-004721-01-
0005, targeted sequences: GCAAGAAGCCGGAGCAUGA, 
GAACAAACACACUGGCUAA, GCUAUGAGUUUAAGAAGUU, 
GCGCAUCGAUCUUCACAAA) by using lipofectamine 2000 
(Thermo Fisher Scientific) according to the manufacturer’s instruc-
tions. Nontargeting siRNA served as control (Dharmacon, D-001206-
14-05, targeted sequences: UAAGGCUAUGAAGAGAUAC, 
AUGUAUUGGCCUGUAUUAG, AUGAACGUGAAUUGCUCAA, 
UGGUUUACAUGUCGACUAA). Cells were incubated for 6 hours 
in Opti-MEM (11058-021; Gibco) with lipofectamine and siRNAs. 
After removal of transfection medium, SMCs were incubated with 
SMC medium with 5% fetal bovine serum for 48 hours. Then, cells 
were cultured in serum-free SMC medium for 24 hours. Medium was 
collected for protein measurements. Cells were harvested for quanti-
tative PCR and Western blot analyses. Major Resources Table is given 
in the online-only Data Supplement. Four milliliters of conditioned 
media was concentrated using 0.5 mL columns with 3 kDa filter 
(Amicon Ultra Centrifugal Filter Device; 3 KD). Five hundred mil-
liliters of samples was added each time and centrifuged at 14 000g 
for 40 minutes at 4°C until the residual volume was around 30 μL. 
Samples were then washed twice using 500 μL of 0.1% SDS each 
time. Protein concentrates were then used for Western blots. After 
conditioned medium collection, cell layers were washed 3× with cold 
PBS to remove the residual medium. Cells were scraped off in cold 
PBS and spun for 1 minute at 15 000g. One hundred milliliters of 1× 
lysis buffer with 1:100 proteinase inhibitors, 25 mmol/L of EDTA was 
added to cell pellets. After resuspension, lysed cell pellets were vor-
texed and incubated for 20 minutes on ice. Protein concentration was 
measured using a BCA protein assay kit before Western blot analyses.
Immunofluorescence Staining in 
Human Aortic Specimen
Human aortic tissues were collected from patients undergoing AsAo 
replacement surgery at St. George’s Hospital according to the local 
Research Ethics Committee (London, REC No 08/H0803/257). Aortic 
tissues were fixed in 10% formalin and then embedded with paraffin. 
For antigen retrieval, chondroitinase ABC was applied on 5 μm tissue 
sections for 2 hours at 37°C. After blocking with 10% fetal bovine 
serum for 1 hour, sections were coincubated with primary antibodies 
to full-length versican and versican neoepitope DPEAAE overnight 
at 4°C. Species-matched isotype IgGs were used as negative controls. 
The appropriate secondary antibody was used for 1 hour at room tem-
perature. Nuclei were stained with DAPI (1:1000 dilution) for 5 min-
utes. The images were visualized with an inverted Nikon Spinning 
disc confocal unit and acquired using NIS-elements 4.0 software.
Statistical Analysis
GraphPad Prism software 7 was used for the analysis. For each 
experiment, Shapiro–Wilk normality test was applied to test the dis-
tribution of the data. If the data were not normally distributed, a non-
parametric test was used. The appropriate tests and post hoc analysis 
were chosen according to the data distribution as specified in each 
figure legend. Data are represented as mean±SD. For proteomics, sta-
tistical analysis was not performed if a protein was undetectable in 
the majority of samples from both groups compared. This is denoted 
as not applicable. Data from discovery proteomics are presented as 
normalized total ion current. Data obtained from targeted proteomics 
are presented as peak area and adjusted according to the total ion 
intensity for each sample. The aortic diameters are represented as 
box and whisker plots, with 75th and 25th percentiles; bars represent 
maximum and minimum values. Differences were assessed using a 
2-way ANOVA and Sidak post hoc test. For all statistical analysis, 
P<0.05 was deemed significant.
Results
ADAMTS Expression in the Murine Aorta
Transcript levels of Adamts5 were higher in the aortic arch 
compared with the other aortic regions, along with transcript 
levels of the large aggregating proteoglycans versican (Vcan) 
and aggrecan (Acan), 2 ADAMTS-5 substrates, which were 
most highly expressed in the arch. Expression of Tgfb1 and 2 
and Tgfbr2 and 3 were also higher in the arch compared with 
the abdominal aorta. In contrast, Adamts1 and Adamts4 and 
hyaluronan and proteoglycan link protein 1 (Hapln1) showed 
lower transcript levels in the arch compared with other regions 
of the murine aorta (Figure 1).
Aortic Dilatation in Adamts5Δcat Mice
Loss of ADAMTS-1 has recently been implicated in TAA.3 
Thus, we assessed aortic dilatation in mice lacking the catalytic 
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domain of Adamts5 (Adamts5Δcat).21 Hypertension was induced 
in Adamts5+/+ and Adamts5Δcat mice by AngII infusion for 4 
weeks (Figure I in the online-only Data Supplement). AngII 
treatment was associated with increased aortic dilatation in 
Adamts5Δcat mice (Figure 2A and 2B); significant differences 
compared with Adamts5+/+ were observed both in the aortic 
root, in particular in the aortic annulus, and the AsAo. Notably, 
the increased aortic dilatation in Adamts5Δcat mice occurred 
despite an attenuated rise in systolic and diastolic blood pres-
sure after 27 days of AngII treatment (Figure 2C). The aor-
tic phenotype and the blood pressure changes in Adamts5Δcat 
mice bear a strong resemblance to the one recently described 
in mice with Adamts1 haploinsufficiency.3
Vascular Substrates of ADAMTS-1 and ADAMTS-5
To identify vascular substrates of ADAMTS-1 and 
ADAMTS-5, murine aortas were subjected to overnight incu-
bation with either ADAMTS-1 or ADAMTS-5 (50 pmol L−1 
mg−1 tissue at 37°C; Figure 3A). Aortas incubated in buffer 
only served as control. The proteins released into the diges-
tion buffer were separated by SDS-PAGE, subjected to in-gel 
tryptic digestion, and analyzed by liquid chromatography-
tandem mass spectrometry. Among the identified extracel-
lular proteins, proteins with differential release on digestion 
by ADAMTS-1 and -5 include known substrates such as 
versican (CSPG2; Figure 3B; Table I in the online-only 
Data Supplement). Detailed examination of the gel-liquid 
chromatography-tandem mass spectrometry data revealed 
the presence of proteolytic products (Figure 3C), that is, for 
CSPG2, CO6A6 (collagen type VI α-6), FINC (fibronectin), 
and LRP1. However, proteolytic cleavage may occur without 
differential release into the digestion buffer, that is, a higher 
number of MS/MS spectra for biglycan (PGS1) and COCA1 
(collagen type XII α-1) were identified in-gel segments below 
the expected molecular weight of the full-length protein indic-
ative of proteolysis. Again, this includes known substrates of 
ADAMTS-5, such as PGS1.22
Proteomics Analysis of Aortas From AngII-
Treated Wild-Type and Adamts5Δcat Mice
To analyze the changes in ECM composition on loss of 
ADAMTS-5 activity, aortas from AngII-treated Adamts5+/+ 
and Adamts5Δcat mice were subjected to a 3-step sequen-
tial extraction procedure: pretreatment with 0.5 mol/L 
NaCl followed by decellularization with 0.08% SDS and a 
final incubation step with 4 mol/L GuHCl to solubilize the 
ECM (Figure 4A). Using a discovery proteomics approach, 
along with MFAP5 (microfibrillar-associated protein 5), 
Figure 1. Gene expression along the murine aorta. Relative gene expression of Adamts1 (a disintegrin and metalloproteinase with throm-
bospondin motifs 1), Adamts4 and Adamts5, versican (Vcan), aggrecan (Acan) and hyaluronan and proteoglycan link protein 1 (Hapln1), 
and Tgfb1 (transforming growth factor-β1), Tgfb2 and Tgfb3 and Tgbr1, Tgbr2 and Tgbr3 in the aortic arch (A), descending (D) and 
abdominal (Ab) aorta (n=6). β-actin was used as reference gene. Gene expression levels in the arch served as reference. Values are given 
as mean±SD; *P<0.05, **P<0.01, ***P<0.001 by Friedman test with Dunn post hoc comparison.
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versican (CSPG2) was returned as more abundant in aortas 
of AngII-treated Adamts5Δcat mice (Figure 4B; Table II in 
the online-only Data Supplement). Subsequent targeted pro-
teomics analysis using both N-terminal and C-terminal pro-
teotypic peptides corroborated that versican was elevated in 
AngII-treated Adamts5Δcat mice (Figure 4C; Table III in the 
online-only Data Supplement). TGF-β1 is known to enhance 
versican expression.23 Human arterial SMCs stimulated with 
TGF-β1 showed a rise in versican transcripts (Figure 4D). 
Notably, higher levels of versican were associated with 
increased protein abundance of TGF-β in aortas of AngII-
treated Adamts5Δcat mice (Figure 4E; Figure II in the online-
only Data Supplement). Gene expression levels of Tgfb1 and 
2 and their receptors Tgfbr1-3 were significantly higher in 
Adamts5Δcat mice at baseline (Figure III in the online-only 
Data Supplement). Interestingly, Adamts1 transcripts were 
Figure 2. Aortic dilatation in Adamts5Δcat (mice lacking the catalytic domain of a disintegrin and metalloproteinase with thrombospondin 
motifs 5) mice. A, Representative ultrasound images. Red dashed lines mark areas considered for aortic diameter measurements. B, 
Maximal diameters of the aortic ring (AoR; aortic annulus [AoAn] and sinuses of Valsalva [SiVa]), ascending aorta (AsAo), and abdominal 
aorta (AbAo) from AngII (angiotensin II)-treated (Adamts5+/+, n=6 and Adamts5Δcat, n=5) and untreated (Adamts5+/+, n=9 and Adamts5Δcat, 
n=9) mice. Adamts5+/+ and Adamts5Δcat mice are represented using burgundy and purple color, respectively. C, Systolic and diastolic 
blood pressure measurements at day 0, 5, and after 27 days of AngII infusion in Adamts5+/+ (n=6) and Adamts5Δcat mice (n=4). Data points 
are mean±SD; P values derived from a 2-way ANOVA (aortic diameter) and 1-way ANOVA (blood pressure) with Sidak correction. *P<0.05, 
**P<0.01.
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markedly elevated in Adamts5Δcat mice, suggesting a com-
pensatory increase of ADAMTS-1 on loss of ADAMTS-5 
activity.
Versican Cleavage in Aortas of Adamts5Δcat Mice
Versican was the most differentially regulated ECM pro-
tein in aortas from Adamts5Δcat mice treated with AngII 
(Figure 4B). It was also returned as one of the major sub-
strates of ADAMTS-1 and -5 in the analysis of aortic explants 
(Figure 3B). Therefore, we focused on ADAMTS-mediated 
versican processing. ADAMTS activity results in the release 
of a specific versican fragment ending with the DPEAAE441 
sequence,11,24 named versikine.25 This signature cleavage site 
of ADAMTS activity can be detected using a neoepitope anti-
body (Figure 5A). As expected, aortas from Adamts5Δcat mice 
displayed reduced versikine; the 65 kDa band is representa-
tive of versikine (Figure 5B). Even after AngII treatment, less 
versikine was observed in Adamts5Δcat mice. This highlights 
the dependence on ADAMTS-5 activity for versicanolysis in 
AngII-induced aortic remodeling (Figure 5C).
Compensatory Increase of ADAMTS-1 
in Aortas of Adamts5Δcat Mice
Because of different processing, ADAMTS-1 can be found in 
2 forms, a larger cell layer and ECM-associated version and 
a smaller, soluble version (Figure 5A).26 Immunoblotting for 
ADAMTS-1 performed on total aortic tissue lysates revealed 
that the loss of ADAMTS-5 activity was accompanied by 
an increase in the smaller, soluble form of ADAMTS-1 (65 
kDa). This was exacerbated after AngII treatment. In con-
trast, the larger, ECM-associated ADAMTS-1 form (79 kDa) 
was detected almost exclusively in the wild-type group. 
The increase in soluble ADAMTS-1 suggests a cross-talk 
between members of the ADAMTS protease family; how-
ever, this compensatory upregulation did not result in the 
complete rescue of ADAMTS-mediated versican cleavage 
(Figure 5C).
Reduced LRP1 in AngII-Treated 
Aortas of Adamts5Δcat Mice
To further investigate the molecular mechanisms, associated 
with the loss of ADAMTS-5 activity, we analyzed LRP1, a 
receptor implicated in the endocytosis of ADAMTS proteases. 
LRP1 was identified as a vascular target of ADAMTS-1 and -5 
(Figure 3). LRP1 was profoundly reduced in aortas of AngII-
treated Adamts5Δcat mice (Figure 5C; Figure IV in the online-
only Data Supplement). LRP1 staining was mainly observed 
in SMCs of mouse aortas (Figure 6A). Next, we silenced 
LRP1 expression in primary human aortic SMCs. Silencing 
LRP1 did not affect ADAMTS1 gene expression but markedly 
reduced expression of ADAMTS5 (Figure 6B). Consequently, 
Figure 3. Proteomics to identify vascular targets of ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs)-1 and 
-5. A, Murine aortas were subjected to overnight incubation with either 50 pmol/L ADAMTS-1 (+ATS1) or 50 pmol/L ADAMTS-5 (+ATS5) 
at 37°C. Aortic explants incubated in buffer served as control. B, Unsupervised hierarchical clustering of the differentially released ECM 
(extracellular matrix) proteins (55 proteins were tested by Kruskal–Willis test, and 13 were found differentially regulated; P<0.05) in the 
supernatants of mouse aortas as identified by proteomics (n=3). The blue–red heat map represents normalized spectral counts highlight-
ing differences in proteins released from aortic explants. C, Spectral evidence for fragmentation. The color-coded heat map represents 
the total number of identified spectra in each gel band and visualizes the fragmentation of ECM proteins. Color scales for heat maps rep-
resent maximum and minimum number of spectra identified in each group. COCA1 indicates collagen type XII a1 chain; CO6A6, collagen 
type VI a6 chain; CSPG2, versican; FINC, fibronectin; LC-MS/MS, liquid chromatography-tandem mass spectrometry; LRP1, low-density 
lipoprotein receptor-related protein 1; and PGS1, biglycan. by guest on A
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versikine was barely detectable in the conditioned media 
of SMCs transfected with an siRNA to LRP1. Moreover, in 
agreement with our results in AngII-treated Adamts5Δcat mice, 
we observed a concomitant increase in ADAMTS-1 on repres-
sion of LRP1 (Figure 6C; Figure V in the online-only Data 
Supplement). Thus, these in vitro experiments complement 
our in vivo findings and establish a link between LRP1 and 
ADAMTS-5–mediated versican cleavage.
Versican Cleavage in Human Aortic Aneurysms
Although differences in versican abundance have been 
reported in human abdominal aortic aneurysms,27 versi-
kine has not been localized yet in human AsAo aneurysms. 
Immunofluorescence staining was performed for versican and 
versikine. Versican staining was seen throughout the aortic 
wall, whereas versikine was localized predominantly in the 
outer media and the subintimal layer of the AsAo aneurysm 
(Figure 6D). These data confirm the presence of ADAMTS-
specific versican cleavage in human ascending TAA tissue.
Discussion
We have characterized regional differences in ADAMTS 
expression along the murine aorta and used proteomics to eval-
uate the effect of loss of ADAMTS-5 activity on aortic ECM 
remodeling. We demonstrated that deficiency of ADAMTS-5 
affects ADAMTS-1 gene expression, protein abundance, and 
processing and resulted in aortic dilatation similar to the phe-
notype recently described in Adamts1-haploinsufficient mice.3
Figure 4. ECM (extracellular matrix) proteomics of AngII (angiotensin II)-treated murine aortas. A, ECM proteomics workflow. B, ECM 
extracts of the entire aorta from AngII-treated Adamts5+/+ (a disintegrin and metalloproteinase with thrombospondin motifs; n=6) and 
Adamts5Δcat (n=5) mice were analyzed using discovery proteomics. Black dots represent proteins differentially regulated between the 
groups (P<0.05). Statistical significance was calculated using Mann–Whitney test (76 ECM and ECM-associated proteins were tested, 
and 2 were found differentially regulated). C, Two different proteotypic peptides (ie, N terminal and C terminal) were chosen to validate 
levels of versican in aortic tissue using targeted proteomics. Peak area values of versican in Adamts5+/+ served as reference for N-terminal 
and C-terminal peptides. Statistical significance was calculated using unpaired Student t test. D, Internal mammary artery smooth muscle 
cells (SMCs) from 4 donors were incubated with TGF (transforming growth factor)-β1. Gene expression of versican was assessed by 
quantitative PCR. Gapdh was used as internal control. Statistical significance was calculated using unpaired Student t test. E, Immunob-
lots performed on total protein lysates reveal an increase in full-length versican and TGF-β in aortas of AngII-treated Adamts5Δcat mice 
(n=4 per group). CSPG2 denotes versican; GuHCl, guanidine hydrochloride; LC-MS/MS, liquid chromatography-tandem mass spectrom-
etry; and MFAP5, microfibrillar-associated protein 5.
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ADAMTS Proteases in Murine Aortas
ADAMTS-1 and ADAMTS-5 are highly expressed in murine 
aortas. We have previously demonstrated that ADAMTS-5 is 
the most potent protease associated with versican cleavage 
in the murine aorta.11 Loss of ADAMTS-5 also results in the 
accumulation of aggrecan.12 To investigate the contribution of 
ADAMTS-5 in ECM remodeling during aortic aneurysm for-
mation, a mouse model lacking ADAMTS-5 activity was used. 
Administration of AngII for 4 weeks exacerbated aortic dila-
tation in Adamts5Δcat mice, with a significantly greater diam-
eter in the AsAo where Adamts5 expression is the highest in 
Adamts5+/+ mice. Moreover, Adamts5Δcat mice showed a lower 
blood pressure in response to AngII stimulation. Interestingly, 
a recent study reported a similar reduction in blood pressure in 
Adamts1-haploinsufficient mice.3 Also other ADAMTS prote-
ases have been implicated in the vasculature and the regula-
tion of blood pressure.28
Proteomics to Identify Vascular Substrates
In the current study, we used proteomics for the analysis of 
aortic ECM changes associated with loss of ADAMTS-5 
activity. By using proteomics, we found that versican was 
Figure 5. ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs)-1 cannot compensate for the lack of ADAMTS-5 
activity. A, Left, Schematic representation of ADAMTS-mediated versican processing. The signature cleavage site for ADAMTS activ-
ity gives rise to an N-terminal versican fragment (versikine) and is recognized by a neoepitope antibody to the DPEAAE amino acid 
sequence. Right, Schematic representation of ADAMTS-1 processing. Processing by MMPs (matrix metalloproteinases) gives rise to a 
truncated, soluble form of ADAMTS-1 (65 kDa). B, C, Immunoblots using neoepitope antibodies to versikine were performed on aortic 
ECM (extracellular matrix) extracts from untreated and AngII (angiotensin II)-treated mice (n=5 per group). Immunoblots for ADAMTS-1 
and LRP1 (low-density lipoprotein-related protein 1) were performed on total protein lysates of untreated and AngII-treated mice (n=5 and 
n=4 per group, respectively). Densitometry for the versican V1 fragment (versikine) and ADAMTS-1. Bars represent mean±SD. Statistical 
significance was calculated using unpaired Student t tests. *P<0.05, **P<0.01.
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more abundant in AngII-treated Adamts5Δcat mice. Versican is 
one of the most abundant large aggregating proteoglycans in 
the aorta.16 Tissue accumulation of versican has been linked 
to the loss of fibrous ECM organization.29 Because we failed 
to detect changes in versican gene expression in Adamts5Δcat 
mice (data not shown), differences in versican protein abun-
dance are most probably related to post-translational process-
ing rather than protein synthesis. Versican is a well-known 
substrate of ADAMTS proteases.30 The release of versikine 
was also observed after incubation of human aortic tissues 
with either ADAMTS-1 or ADAMTS-5.11 The absence of the 
catalytic activity of ADAMTS-5 seems to result in the build-
up of unprocessed versican in the aortic wall, as previously 
observed in valve tissue of Adamts5Δcat mice.13
ADAMTS-Mediated Versicanolysis
Versican can be cleaved by different proteases including 
MMPs,31 plasmin,32 and several members of the ADAMTS 
family. The latter harbor sequence motifs specific to large 
aggregating proteoglycans, including versican.16 The neo-
epitope DPEAAE at position 441 of versican is generated 
after ADAMTS cleavage.25 The neoepitope antibody recog-
nizes only the cleaved product of versican, corresponding 
to the N terminus of the proteoglycan.25 This fragment was 
reduced in Adamts5Δcat mice, which is in agreement with 
our previous report.11 As demonstrated in this study, this 
effect is exacerbated after AngII infusion; chronic infusion 
of AngII enhanced the release of versikine in murine aortas. 
In AngII-treated Adamts5Δcat mice, immunoblotting revealed 
Figure 6. Effects of LRP-1 (low-density lipoprotein-related protein 1) and detection of versikine in human ascending aortic aneurysms. 
A, LRP1 localization in the ascending aorta of Adamts5Δcat (mice lacking the catalytic domain of a disintegrin and metalloproteinase with 
thrombospondin motifs 5) mice. Colocalization of LRP1 (Alexa 647, displayed in red) and αSMA (Alexa 568, displayed in green) in the 
mouse aorta as visualized by immunofluorescence. Elastin fibers are in white (autofluorescence captured with 488 nm laser excitation). 
Control sections stained with isotope IgGs. Magnification ×60, scale bars=10 mm. B, Relative gene expression of ADAMTS1, LRP1, 
ADAMTS5, and VCAN in human aortic smooth muscle cells (SMCs) treated for 72 h with LRP1 siRNA (n=3). β-actin was used as refer-
ence gene. Data points are mean±SD. Statistical significance was calculated using a paired Student t tests. *P<0.05. C, Immunoblotting 
performed on cell lysate and conditioned media after transfection (n=3). Silencing LRP1 results in a decrease in versikine and an increase 
in ADAMTS-1 in the conditioned media. D, Localization of versican (Alexa568, displayed in green) and versikine (Alexa 647, displayed in 
red) in human ascending aortic aneurysms as visualized by immunofluorescence. Magnification ×20, scale bar=200 mm and ×60, scale 
bar=20 mm.
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a marked reduction of the ADAMTS-specific DPEAAE neo-
epitope demonstrating the importance of ADAMTS-5 for 
versican cleavage. Versikine has been suggested to stimulate 
SMC migration and induce cell apoptosis during develop-
ment.33,34 Little residual ADAMTS activity was detectable in 
aortas of AngII-treated Adamts5Δcat mice. The latter is most 
likely attributable to ADAMTS-1, which was increased in 
Adamts5Δcat mice. ADAMTS-1 is known to be processed 
into 2 active forms: (1) an ECM associated and (2) a soluble 
form, generated after MMP cleavage of the thrombospondin 
domain at the C terminus. The loss of ADAMTS-5 activ-
ity led to a rise in the soluble form of ADAMTS-1, and this 
effect was exacerbated after AngII treatment. The removal of 
the last thrombospondin domain renders ADAMTS-1 more 
similar to ADAMTS-5, suggesting that the release of soluble 
ADAMTS-1 could be a compensatory response to the loss of 
ADAMTS-5. ADAMTS-1, however, does not seem to be suf-
ficient to compensate for the lack of ADAMTS-5 activity, at 
least with regards to versican cleavage.
Effects on TGF-β
The increase in total versican levels was associated with a 
concomitant upregulation of TGF-β in Adamts5Δcat mice after 
AngII treatment. TGF-β is known to induce the expression 
of different proteoglycans, including versican.23 In line with 
this finding, stimulation of arterial SMCs with TGF-β1 led 
to an increase in versican expression. Interestingly, it has 
also been shown that the latent form of TGF-β can be associ-
ated and subsequently activated by the C-terminal region of 
ADAMTS-1, thereby enhancing the inflammatory response 
in liver fibrosis.35 In agreement with these results, we found 
a direct correlation between ADAMTS-1 and TGF-β regula-
tion in ADAMTS-5Δcat mice on AngII treatment. The increased 
levels of versican, TGF-β, and ADAMTS-1 were accompa-
nied by an increased aortic dilatation in these mice after AngII 
treatment. Dysregulation of TGF-β has been linked to aneu-
rysm development.36,37 However, the mechanisms of TGF-β–
mediated aneurysm formation have not completely elucidated 
yet. The present study highlights an effect of ADAMTS activ-
ity on TGF-β bioavailability.
Regulation by LRP1
LRP1 has previously been implicated in aortic aneurysm for-
mation in humans and mice14,38,39; however, the exact mech-
anisms are unclear. LRP1 is involved in different cellular 
processes, such as lipid homeostasis, signal transduction, and 
endocytosis.40,41 LRP1 also acts as a protease sink responsi-
ble for cellular uptake of ADAMTS-5 from the extracellular 
space.42 Moreover, LRP1 can bind TGF-β1 and TGF-β2 and 
thereby inhibit cell proliferation and regulate vascular remod-
eling, respectively.43 After AngII treatment, LRP1 was less 
abundant in aortas of Adamts5Δcat mice. This was accompa-
nied by an increase in the short soluble form of ADAMTS-1 
as a possible mechanism to compensate for the lack of 
ADAMTS-5. This coordinated regulation is consistent with a 
feedback mechanism between ADAMTS-1 and LRP1 and a 
compensatory downregulation of LRP1 in Adamts5Δcat mice to 
increase the extracellular availability of ADAMTS proteases. 
Silencing LRP1 in human aortic SMCs reduced ADAMTS5 
expression and resulted in a loss of ADAMTS-mediated versi-
can cleavage. Again, this was accompanied by an increase of 
ADAMTS-1 in the conditioned media. These findings expand 
on a previous report that the deletion of Lrp1 expression in 
SMCs augmented AsAo dilatation in AngII-treated mice.14
Limitations of the Study
A mouse model of AngII infusion was used to study the 
effects of ADAMTS-5 on aortic dilatation, which may not 
recapitulate all aspects of human aneurysmal disease, in par-
ticular with regards to hemodynamics and mechanotransduc-
tion.44,45 Also, the relative importance of different members of 
the ADAMTS family may differ between species. In human 
aneurysmal disease, previous studies have shown increased 
protein and transcript levels of ADAMTS-1 and -4 in TAA.10,46 
Consistent with our findings, a recent study reported decreased 
ADAMTS5 expression and increased deposition of proteogly-
cans, such as aggrecan and versican in human TAA.8 Finally, 
changes in ADAMTS activity are likely to be associated with 
the proteolysis of other proteins apart from versican.
Conclusions
At present, the clinical management of aneurysms is ham-
pered by our limited knowledge about the cause and patho-
genetic mechanisms involved in the disease. Evidence is 
emerging that ECM processing by members of the ADAMTS 
protease family could play an important role in the progres-
sion of aortic dilatation.3 The present study takes advantage of 
proteomics to define vascular substrates of ADAMTS prote-
ases. LRP1, which has been involved in aneurysm pathology 
in both human and mice, seems to be linked to ADAMTS-5 
and ADAMTS-5–mediated versican cleavage. In mice lack-
ing ADAMTS-5 activity, AngII infusion results in decreased 
versicanolysis, an increase in full-length versican and TGF-β, 
but reduced LRP1 compared with wild-type controls. Mice 
lacking ADAMTS-5 activity also showed increased aor-
tic dilatation in response to AngII infusion despite a lower 
blood pressure. A compensatory rise in ADAMTS-1 could 
not prevent aortic dilatation in Adamts5Δcat mice, suggesting 
the greater relative importance of ADAMTS-5 in this context. 
Further studies are needed to explore the ADAMTS protease 
family as a target for therapeutic approaches aimed to reduce 
or halt dilatation of the aorta resulting in dissection.
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Highlights
• Expression of ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs)-5 and the large aggregating proteoglycans is higher 
in the aortic arch compared with the abdominal aorta.
• AngII (angiotensin II) treatment in Adamts5Δcat mice is associated with increased dilatation of the ascending aorta.
• Loss of ADAMTS-5 activity induces an accumulation of versican on AngII treatment.
• This is accompanied by an increase in TGF-β (transforming growth factor-β) levels and a compensatory upregulation of soluble ADAMTS-1.
• Silencing of LRP1 (low-density lipoprotein-related protein 1) in human aortic smooth muscle cells reduces ADAMTS-5 expression, attenuates 
ADAMTS-mediated versican cleavage, and increases ADAMTS-1.
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Major Resources Tables 
 
Animals 
 
Species/Strain Vendor or Source Background Strain Sex 
Wildtype mice 
The Jackson 
Laboratory C57BL/6J male 
Adamts5∆cat The Jackson Laboratory 
129P2/OlaHs backcrossed 5 
times onto C57BL/6J, one 
additional backcross was 
performed to generate the 
littermates for experiments 
male 
 
 
Primary Antibodies 
 
Target antigen Vendor or Source Catalog # 
Working 
concentration 
Lot #  
Neoepitope on 
versican 
generated by 
ADAMTS 
cleavage 
Abcam ab19345 WB: 1µg/ml IHC: 10µg/ml GR314383-6 
Full-length 
versican Millipore AB1033 WB: 0.5µg/ml 2867545 
Full-length 
versican Millipore MABT161 IHC: 2.5µg/ml 2702191 
ADAMTS-1 Thermo Fisher 720329 WB: 2µg/ml SA246704 
TGFß Abcam ab179695 WB: 0.512µg/ml GR262076-2 
LRP1 Abcam ab92544 WB: 0.512µg/ml IHC: 4.6µg/ml GR259330-25 
GAPDH Sigma G8795 WB: 0.05µg/ml 056M-4856V 
Alpha smooth 
muscle actin Abcam Ab21027 IHC:4µg/ml GR309074-1 
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Secondary Antibodies 
Vendor or Source Target Species Catalog # 
Working 
concentration 
Lot #  
Jackson 
ImmunoResearch Rabbit 211-032-171 WB: 80ng/ml 130846 
Jackson 
ImmunoResearch Mouse 115-035-174 WB: 80ng/ml 129518 
Invitrogen Rabbit A21069 IHC: 2.5 µg/ml 1736974 
Invitrogen Mouse A21203 IHC: 2.5 µg/ml 987237 
Invitrogen Rabbit A31573 IHC: 2.5 µg/ml 1900251 
Invitrogen Goat A11055 IHC: 2.5 µg/ml 1081957 
 
Cultured Cells 
Name Vendor or Source Sex (F, M, or unknown) 
Human aortic SMCs Lonza, US Male 
Human internal mammary 
artery SMCs 
Dr. Karen Porter, Leeds 
Institute of Cardiovascular 
and Metabolic Medicine 
Unknown 
 
Material 
Name Company  Catalog Number 
1.Chemicals   
Cocktail of proteinase inhibitor Thermo Scientific 51101 
Chloroform Sigma-Aldrich C2432 
Phosho STOP Roche 4906837001 
Cell Lysis buffer Cell Signalling 9803 
NuPAGE MOPS SDS Running Buffer 
(20X) Life Technologies NP0001-02 
EDTA Sigma-Aldrich E9884 
EGTA Sigma-Aldrich E3889 
Ethanol VWR 437433T 
Formalin Sigma-Aldrich HT501128 
Guanidine hydrochloride Sigma-Aldrich G3272 
H218O Taiyo Nippon Salso FO3-0027 
Iodoacetamine Sigma-Aldrich A3221 
Glycine Sigma-Aldrich G8896 
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Lipofectamine 2000 Invitrogen 12566014 
Methanol Fisher Chemical A4545K 
Phosphate-buffered saline (PBS), 
10X Lonza 51226 
Ponceau Sigma-Aldrich P7170 
Quiazol Lysis Reagent Qiagen 4053228006220 
Sodium Acetate Sigma-Aldrich S7545 
Sodium Azide Sigma-Aldrich 08591 
Sodium Chloride Sigma-Aldrich S9888 
Sodium dedrcyl sulfate, SDS Sigma-Aldrich 466143 
Sodium Citrate dihydrate Sigma-Aldrich W302600 
Super Script VILO MasterMix Invitrogen 11755050 
TaqMan Universal PCR Master Mix Applied Biosystem 4324018 
Triethylammonium bicarbonate 
(TEAB) Sigma-Aldrich 11268 
Trifluoroacetic acid (TFA) Sigma-Aldrich T62200 
Thiourea Sigma-Aldrich T8656 
Tris-hydrochloride (Tris-HCl) Sigma-Aldrich T3253 
Triton X-100 Sigma-Aldrich T8787 
Trizma base Sigma-Aldrich T1503 
Tween-20 Sigma-Aldrich P7949 
Urea Sigma-Aldrich U1250 
2.Enzymes   ⍺2-3,6,8,9-neuroaminidase 
(Sialidase) EDM Millipore 362280 (KP0012) 
β1,4-galactosidase EDM Millipore 362280 (KP0004) 
β-N-acetylglucosaminidase EDM Millipore 362280 (KP0013) 
Chrondroitinase ABC Sigma-Aldrich C3667 
Endo-⍺-N-acetylgalactosaminidase 
(O-glycosidase) 
EDM Millipore 362280 (KP0011) 
Heparinase II Sigma-Aldrich H6512 
Keratanase Sigma-Aldrich G6920 
PNGaseF (N-Glycosidase) EDM Millipore 362280 (KP0001) 
Trypsin Thermo Scientific 90057 
3.Reagent kits   
NuPAGE Novex BisTris Acrylamide 
gels 
Thermo Scientific NP0322PK2 
Pierce BCA Protein Assay kit Thermo Scientific 23227 
miRNeasy Mini kit Qiagen 4053228006220 
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TaqMan Probes 
Species Target Assay 
Mouse Vcan Mm01283063_m1 
Mouse Acan Mm00545794_m1 
Mouse Hapln1 Mm00488952_m1 
Mouse Adamts1 Mm01344169_m1 
Mouse Adamts4 Mm00556068_m1 
Mouse Adamts5 Mm00478620_m1 
Mouse Tgfb1 Mm01178820_m1 
Mouse Tgfb2 Mm00436955_m1 
Mouse Tgfb3 Mm00436960_m1 
Mouse Tgfbr1 Mm00436964_m1 
Mouse Tgfbr2 Mm03024091_m1 
Mouse Tgfbr3 Mm00803538_m1 
Mouse Actb Mm00607936_s1 
Human VCAN Hs00171642_m1 
Human GAPDH Hs02786624_g1 
Human ADAMTS1 Hs00199608_m1 
Human ADAMTS4 Hs00192708_m1 
Human ADAMTS5 Hs00199841_m1 
Human LRP1 Hs00233856_m1 
Human ACTB Hs99999903_m1 
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ONLINE METHODS 
In vitro metalloprotease digestion assay. Murine aortic specimens were dissected 
into smaller pieces and washed 5 times in ice-cold, 1X PBS. The tissue blocks were then 
mixed with 10 volumes metalloprotease reaction buffer (10mM CaCl2, 120mM NaCl and 
50mM Trizma base, pH 7.5), which was either used neat (control) or supplemented with 
different concentrations (50-100pM) of recombinant proteins; murine ADAMTS-1 and murine 
ADAMTS-5, all purchased from R&D Systems. The samples were incubated for 24hrs at 
37°C. Subsequently, the released proteins in the tissue supernatants were deglycosylated. 
For protein deglycosylation, samples were resuspended in deglycosylation buffer (150mM 
NaCl, 50mM sodium acetate pH 6.8, 10mM EDTA) for 16hrs at 37°C containing a 
combination of enzymes for GAG-removal enzymes: chondroitinase ABC (1:100), endo-
β1,4-galactosidase (1:500) and heparinase II (1:500). The deglycosylated proteins were 
separated by gel electrophoresis prior to digestion and LC-MS/MS.  
Gel-LC-MS/MS analysis of aortic supernatants. Proteins released from aortas on 
incubation with ADAMTS-1 and ADAMTS-5 were first separated by SDS-PAGE. Sample 
buffer (100mM Tris pH 6.8, 40% glycerol, 0.2% SDS, 2% b-mercaptoethanol and 0.02% 
bromophenol blue) was added to the deglycosylated extracts and boiled at 96°C for 10min 
prior to separation on 4-12% Bis-Tris gradient gels (Life Technologies, Cat No. 
EC60385BOX). Electrophoresis was performed at 130-170V for 100-120min in 1x NuPage 
MOPS SDS Running Buffer (Life Technologies). Proteins were silver-stained for 
visualization and gel lanes were cut into 10 consecutive pieces. All gel bands were 
subjected to in-gel digestion with trypsin using an Investigator ProGest (Digilab) robotic 
digestion system. Tryptic peptides were lyophilized, reconstituted with 0.05% TFA in 2% 
ACN and separated on a nanoflow LC system (Thermofisher Scientific, Ultimate 3000). 
Peptides were eluted with a 40-min gradient (10–25% B in 35min, 25–40% B in 5min, 90% B 
in 10min, and 2%B in 30min where A is 2% ACN, 0.1% formic acid in HPLC H2O and B is 
90% ACN, 0.1% formic acid in HPLC H2O). The column (Thermofisher Scientific, PepMap 
C18, 25cm length, 75μm internal diameter, 3μm particle size) was coupled to a nanospray 
source (Picoview). Spectra were collected from an Orbitrap mass analyzer (LTQ-Orbitrap 
XL, ThermoFisher Scientific) using full ion scan mode over the mass-to-charge (m/z) range 
450–1600. MS/MS was performed on the top six ions in each MS scan using the data-
dependent acquisition mode with dynamic exclusion enabled. MS/MS peak lists were 
generated by extract_msn.exe and matched to a mouse database (SwissProt_57.15, 16230 
protein entries) using Mascot (version 2.3.01, Matrix Science). Carbamidomethylation of 
cysteine was chosen as a fixed modification and oxidation of methionine, lysine and proline 
were chosen as a variable modifications. The mass tolerance was set at 10ppm for the 
 3 
precursor ions and 0.8Da for fragment ions. Up to two missed cleavages were allowed. 
Scaffold (version 3.0.08, Proteome Software Inc., Portland, OR) was used to calculate the 
spectral counts and to validate MS/MS-based peptide and protein identifications. Peptide 
identifications were accepted if they could be established at greater than 95.0% probability. 
Protein identifications were accepted if they could be established at a minimum of 99.0% 
probability. 
ECM protein extraction. Diced tissue was weighed (8-12mg) and immediately 
placed into Eppendorf tubes containing 1 ml of ice-cold PBS supplemented with 1:100 (v:v) 
of a broad-spectrum protease inhibitor cocktail (Sigma-Aldrich), and 25mM EDTA to ensure 
inhibition of metalloproteinases. After 5 washes with PBS buffer the diced samples were 
incubated with a 0.5M NaCl buffer supplemented with 10mM Tris at pH 7.5, 1:100 (v:v) of a 
proteinase inhibitor cocktail and 25mM EDTA. The volume of the buffer was adjusted to 5:1 
(v:w). Samples were mildly vortexed for 2hrs at room temperature (RT) to solubilize loosely 
bound ECM and ECM-associated proteins, after which the NaCl buffer was collected and 
frozen for later use. Samples were washed briefly in the PBS buffer, followed by incubation 
with 0.08% sodium dodecyl sulphate (SDS) supplemented with proteinase inhibitor cocktail 
and 25mM EDTA (same ratios as for NaCl buffer above). Samples were mildly vortexed for 
2hrs at RT to achieve removal of cellular components, taking particular care to ensure a low 
vortexing speed to avoid mechanical disruption of the ECM. SDS extracts were then 
collected and frozen for later use. The tissue samples were washed briefly with water. 
Finally, the samples were incubated in 4M guanidine hydrochloride buffer (GuHCl) 
supplemented with 50mM sodium acetate at pH 5.8, 1:100 (v:v) of a proteinase inhibitor 
cocktail and 25mM EDTA.  The volume of the buffer was adjusted to 5:1 (v:w) and the 
incubation was performed for 48hrs at RT. GuHCl destabilises the ionic, disulfide-dependent 
protein conformations in large aggregating proteoglycans (PGs), small PGs, cell attachment 
matrix glycoproteins, fibronectins and laminins and basement membrane components. A 
vigorous vortexing speed was used to enhance mechanical disruption of the ECM 
components at this stage. GuHCl extracts were collected and protein concentration was 
measured by spectrophotometry based on the absorbance at 280nm. 
Deglycosylation of ECM extracts. After extraction, 15μg of protein from GuHCl 
extracts were incubated with 100% ethanol (1:10 volume ratio) at -20°C overnight. After 
incubation, proteins were precipitated by centrifugation at 16,000 g for 1h at 4°C. 
Supernatants were carefully removed and protein pellets were dried using a vacuum 
centrifuge (ThermoFisher Scientific). Precipitation ensures removal of GuHCl, which would 
interfere with later steps (i.e. enzymatic digestions). For protein deglycosylation (i.e. removal 
of glycans attached to proteins), a two-step protocol was pursued. In the first step, samples 
were resuspended in deglycosylation buffer (0.2mol/L Tris, 0.2mol/L sodium acetate, 
 4 
0.1mol/L EDTA, 0.05mol/L sodium phosphate, pH 6.8) containing a combination of enzymes 
for glycosaminoglycan (GAG)-removal (as mentioned above) and three additional enzymes 
that ensure debranching of sugar residues: α2-3,6,8,9-Neuraminidase (from Arthrobacter 
ureafaciens), which cleaves all non-reducing terminal branched and unbranched sialic acids; 
β1,4-Galactosidase (from Streptococcus pneumonia) releases only β1,4-linked, non-
reducing terminal galactose from complex carbohydrates and glycoproteins; β-N-
Acetylglucosaminidase (from Streptococcus pneumonia) cleaves all non-reducing terminal 
β-linked N-acetylglucosamine residues from complex carbohydrates and glycoproteins (all 
purchased from Merck-Millipore and used at a ratio of 1:200). Endo-α-N-
acetylgalactosaminidase (O-glycosidase from Streptococcus pneumoniae) was added to 
ensure removal of O-glycosylation. This enzyme cleaves serine- or threonine-linked 
unsubstituted Galβ1,3GalNAc. The samples were incubated for 1h at 25°C and 24hrs at 
37°C, at 200rpm. Removal of sugar monomers facilitates the later cleavage by PNGase-F. 
This enzyme cleaves all asparagine-linked oligosaccharides unless α1,3-core fucosylated. 
Importantly, asparagine must be peptide-bonded at both termini. After the first incubation 
step, water was evaporated from the extracts and substituted for an equal amount of H218O 
containing 1:100 PNGase-F (N-glycosidase F). Subsequently, samples were incubated 
under constant agitation, at 37°C for 48hrs. Deglycosylation in the presence of H218O, 
ensures labelling of asparagines with 18O every time a deglycosylation event takes place. 
During LC-MS/MS analysis, detection of 18O in deamidated asparagines is an indirect 
indicator of the presence of N-glycosylation.  
In-solution digestion and C18 clean-up of ECM extracts. Deglycosylated GuHCl 
extracts were denatured by the addition of 9M urea, 3M thiourea (final conc. 6M urea, 2M 
thiourea), and reduced by the addition of 100mM DTT (final conc. 10mM) followed by 
incubation at 37°C for 1h, 240rpm. The samples were then cooled down to RT before being 
alkylated by the addition of 500mM iodoacetamide (final conc. 50mM) followed by incubation 
in the dark for 1h. Pre-chilled (-20°C) acetone (8x volume) was used to precipitate the 
samples overnight at -20°C. Samples were centrifuged at 14,000 g for 25min at 4°C and the 
supernatant subsequently discarded. Protein pellets were dried using a speed vac (Thermo 
Scientific, Savant SPD131DDA), re-suspended in 0.1M TEAB buffer, pH 8.2, containing 
trypsin (Cat No. 90057, Thermo Scientific; 1:50, trypsin:protein) and digested overnight at 
37°C, 240rpm. The digestion was stopped by acidification of the samples with 10% TFA 
(final concentration 1% TFA). Peptide samples were purified using a 96-well C18 spin plate 
(Harvard Apparatus). The resin was activated using 200µl methanol and centrifuged at 1,000 
g for 1min. Wash steps included 200µl of 80% ACN, 0.1% TFA in H2O, and three 
equilibration steps using 200µl of 1% ACN, 0.1% TFA in H2O with centrifugation (1,000 g for 
1min) after each step. Samples were loaded onto the resin and centrifuged at 2,000 g for 
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1min; the flow-through was reloaded onto the resin a second time and centrifugation 
repeated. The resin was then washed three times with 200 µl 1% ACN, 0.1% TFA in H2O 
(centrifugation at 1,500 g for 1min). Finally, the samples were eluted with 170µl of 50% 
acetonitrile, 0.1% TFA in H2O (centrifugation at 1,500 g for 1min); this step was repeated, 
combining the collected eluate. The eluates were dried using a speed vac (Thermo 
Scientific, Savant SPD131DDA) and re-suspended in 0.05% TFA in 2% ACN for LC-MS/MS 
analysis. 
Discovery proteomics in ECM extracts. The resuspended peptide samples were 
separated on a nanoflow LC system (UltiMate 3000 RSLC nano). Samples were injected 
onto a nano-trap column (Acclaim® PepMap100 C18 Trap, 5mm x 300um, 5µm, 100Å), at a 
flow rate of 25µL/min for 3min, using 0.1% FA in H2O. The following nano LC gradient was 
used to separate the peptides at 0.3µL/min: 0−10min, 4-10% B; 10−75min, 10-30% B; 75-
80min, 30−40% B; 80-85min, 40-99%B, 85-89.8min 99%B, 89.8-90min 99-4%B, 90-120min 
4% B, where A = 0.1% FA in H2O, B = 80% ACN, 0.1% FA in H2O. The nano column 
(Acclaim PepMap100 C18, 50 cm x 75 µm, 3 µm, 100 Å) was kept at 40°C and coupled to a 
nanospray source (Picoview, New Objective, US). Spectra were collected from a Q Exactive 
HF (Thermo Fisher Scientific) using full MS mode (resolution of 60,000 at 200m/z) over the 
mass-to-charge (m/z) range 350–1600. Data-dependent MS/MS scan was performed using 
the top 15 ions in each full MS scan (resolution of 15,000 at 200m/z) with dynamic exclusion 
enabled. Proteome Discoverer (version 2.1.0.81, Thermo Scientific) was used to search raw 
data files against the mouse data-base (UniProtKB/Swiss-Prot version 2016_02, 16683 
protein entries) using Mascot (version 2.3.01, Matrix Science). The mass tolerance was set 
at 10ppm for precursor ions and 20mmu for fragment ions. Trypsin was used as the enzyme 
with up to two missed cleavages being allowed. Carbamidomethylation of cysteine was 
chosen as a fixed modification; oxidation of methionine, lysine and proline, and deamidation 
of asparagine in the presence of 18O water were chosen as variable modifications. Scaffold 
(version 4.7.3, Proteome Software Inc., Portland, OR) was used to validate MS/MS-based 
peptide and protein identifications with the following filters; a peptide probability of greater 
than 95.0% (as specified by the Peptide Prophet algorithm), a protein probability of greater 
than 99.0%, and at least two independent peptides per protein. The normalized total ion 
current (TIC) was used for quantification. 
Targeted proteomics in ECM extracts. A Parallel Reaction Monitoring (PRM) 
method was developed using Skyline software (version 3.6, MacCoss Lab Software). Data 
from the discovery proteomics analysis were used to select proteotypic peptides of ECM and 
related proteins. Precursor ions for proteins of interest that were not detected in the 
untargeted analysis were predicted in silico using SRM Atlas. Skyline was used to optimize 
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retention times. Proteotypic peptides were scheduled using the retention time obtained from 
test experiments with the same LC configuration and eluting gradient; retention time 
windows were set at +/- 4min. The same LC and Q Exactive HF system was used as for 
untargeted analysis but with a 220min LC gradient. After trapping, at a flow rate of 25µL/min 
for 3min, using 0.1% FA in H2O, the following nano-LC gradient was applied at 0.3µL/min: 
0−20min, 4-8% B; 20−200min, 8-25% B; 200−210min, 25−40% B; 210-215min, 40-99% B, 
215-219.8min, 99% B, 219.8-220min, 99-4% B, 220-250min 4% B, where A=0.1% FA in 
H2O, B=80% ACN, 0.1%FA in H2O. Spectra were collected on a Q Exactive HF 
(ThermoFisher Scientific) in PRM mode (MS/MS resolution of 30,000 at 200m/z). An 
isolation window of 2.0 m/z, automatic gain control (AGC) values of 2E5 and a maximum 
injection time of 60ms were used. Fragmentation was performed with a normalized collision 
energy of 28. MS/MS scans were acquired with a first fixed mass of 110.0m/z. The identity 
of a specific peptide was confirmed by the presence of multiple fragment ions at the same 
retention time. The inclusion list is shown in Supplemental Table III. 
Western blot. Aliquots from GuHCl and total protein extracts were mixed with protein 
loading buffer and denatured at 98°C for 5-10min before being briefly centrifuged. Protein 
samples were separated on 4-12% Bis-Tris gradient gels at 130-170V for 100-120min in 1x 
NuPage MOPs SDS Running Buffer. Subsequently, the samples were transferred to 
nitrocellulose membranes in ice-cold transfer buffer (25 mM Tris-Base and 200mM Glycine 
in 20% methanol). Ponceau S red staining was used to ensure efficient transfer and equal 
loading. Next, membranes were blocked in 5% milk in PBS with 0.1% Tween-20 (PBST) for 
1h on a shaker at RT. After a brief wash in PBST, they were incubated overnight with 
primary antibody solution. Please see the Major Resources Table in the Supplemental 
Material. The following day, after three washes in PBST (15min each), the membranes were 
incubated for 1h at RT with the HRP-conjugated secondary antibody diluted in 5% milk in 
PBST, according to the source of the primary antibody. The membranes were then washed 
three times in PBST for 15min and developed using ECL western blotting detection reagent 
using either X-ray films (FUJIFILM) or Chemidoc Touch, Imaging System (BIORAD). 
Immunoblots were quantified by densitometry using Image-J software. 
RNA isolation. RNA extraction was performed using the miRNeasy Mini Kit (Qiagen) 
following the manufacturers’ protocol. For aortic tissue, samples were diced using a scalpel, 
incubated in 700μl of Qiazol Lysis Reagent and homogenised using FastPrep ceramic lysis 
beads (Matrix D, MPBio). Cells were washed twice in cold sterile PBS and lysed in 700μl of 
Qiazol Lysis Reagent. Samples were subsequently incubated at RT for 5min, and then 
vortexed with 140μl of chloroform. The lysate was then incubated for a further 5min at RT 
before being centrifuged for 15min at 12,000 g, at 4°C. 280μl of the upper aqueous phase 
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were transferred to a new tube, mixed with 1.5 volumes of 100% ethanol and transferred into 
a miRNeasy mini column. The remaining centrifugation steps were carried out at RT. The 
column was centrifuged for 1min at 12,000 g and the flow through was discarded, next 700μl 
of RWT buffer was added to the column, centrifuged for 1min at 12,000 g and the flow 
through was discarded. Next, 500μl of RPE buffer were added to the column before a further 
centrifugation step for 1min at 12,000 g. The flow through was discarded and a further 500μl 
of RPE buffer were added to the column before it was centrifuged at 12,000 g for 2min. The 
columns were transferred to clean collection tubes and centrifuged at 15,000 g for 1min, 
before being transferred to a new tube. The RNA was eluted with 30μl of RNase-free water, 
by centrifugation at 10,000 g for 1min. RNA concentration (Abs 260nm) and purity (260/280) 
were measured in 1μl using spectrophotometry (NanoDrop ND-1000, ThermoScientific). 
Integrity of RNA was evaluated using Agilent Bioanalyser System. RNA quality was 
considered acceptable if the RNA integrity number (RIN) was above 7. 
Reverse transcription (RT) and quantitative real-time PCR (qPCR). The RNA was 
reverse-transcribed using random hexamers with SuperScript VILO MasterMix (Invitrogen) 
according to manufacturers’ protocol, with sample preparation being performed on a 
StarChill PCR rack to maintain low temperature. RNA concentration of samples was 
adjusted to contain equal amounts of RNA (250-500ng) in 8μl using RNase-free water. No 
DNase treatment was performed. The reverse transcription reaction was set up by mixing 
the 8μl of RNA with 2μl of SuperScript VILO MasterMix. RT reaction was performed in a 
Veriti thermal cycler (Applied Biosystems) with the following protocol: incubation at 25°C for 
10min followed by 2hrs incubation at 42°C. the reaction was terminated by incubation at 
85°C for 5min. Samples were kept at 4°C for immediate use in the qPCR reaction or stored 
at -20°C. 
The RT product was diluted 1:15 to 1:25 using RNase-free water. TaqMan assays 
using hydrolysis probes (Major Resources Tables) were used for quantitative PCR (qPCR). 
2.25μl of diluted RT product were combined with 2.5μl of TaqMan Universal PCR Master 
Mix, no AmpErase UNG (Applied Biosystems), 0.25μl of TaqMan assays on a MicroAmp 
Optical 384-well reaction plate, using a Bravo Liquid Handling Platform (Agilent). qPCR 
reaction was performed in a ViiA 7 Real-Time PCR System (Applied Biosystems), set to run 
as follows: incubation at 95°C for 10min, followed by 40 cycles of 95°C for 15sec and 60°C 
for 1min. Data was analysed using ViiA 7 software (Applied Biosystems). A minimum of two 
reference genes was used throughout the study and stability of RNA isolation, RT and qPCR 
was determined by variability of and correlation between reference genes. Relative amounts 
of the targets were calculated using the 2-∆∆Cq method,17 with statistical analysis performed 
on ∆Cq values. 
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Supplemental Table I. Extracellular proteins released from mouse aortas on incubation with ADAMTS-1 or ADAMTS-5. 
Identified Proteins  Uniprot 
Accession 
Mr 
(kDa) Control ADAMTS-1 ADAMTS-5 
P-
value 
ADAMTS-1 P97857 106 0±0 42.5±0.4 0±0 0.036 
ADAMTS-5 Q9R001 102 0±0 0±0 15.9±8.4 0.036 
Adipocyte enhancer-binding protein 1 Q640N1 128 24.0±5.4 23.4±1.9 27.2±0.8 0.339 
Adiponectin Q60994 27 2.4±2.2 5.5±2.2 0.6±1.1 0.079 
Aggrecan Q61282 222 0±0 0±0 0.6±1.1 >0.999 
Agrin A2ASQ1 208 0±0 3.3±1.5 3.2±3.0 0.186 
Alpha-2-HS-glycoprotein P29699 37 4.8±2.3 3.6±0.6 2.6±2.2 0.543 
Annexin A2 P07356 39 7.7±6.8 12.0±3.0 17.5±4.5 0.100 
Apolipoprotein A-I Q00623 31 0±0 1.0±1.7 0±0 >0.999 
Apolipoprotein A-IV P06728 45 0.8±1.4 0±0 0±0 >0.999 
Beta-2-glycoprotein 1 Q01339 39 10.7±2.8 6.5±1.5 6.5±0.6 0.071 
Biglycan P28653 42 6.0±3.4 6.5±1.5 7.1±2.9 0.929 
Cell surface glycoprotein MUC18 Q8R2Y2 72 7.7±1.8 9.7±1.0 8.1±1.5 0.296 
Chondroitin sulfate proteoglycan 4 Q8VHY0 252 46.5±12.1 34.4±2.1 40.4±4.8 0.132 
Clusterin Q06890 52 0±0 1.6±2.8 0±0 >0.999 
Collagen alpha-1(I) P11087 138 3.3±1.2 3.2±1.1 2.6±2.5 0.132 
Collagen alpha-1(III) P08121 139 7.9±1.7 8.8±0.9 5.5±0.5 0.050 
Collagen alpha-1(VI) Q04857 108 83.1±6.3 84.1±4.9 89.9±5.8 0.361 
Collagen alpha-1(XII) Q60847 340 7.6±4.0 15.9±1.1 15.9±5.7 0.100 
Collagen alpha-1(XIV) Q80X19 193 68.2±19.5 78.6±3.6 70.5±7.8 0.511 
Collagen alpha-1(XV) O35206 140 42.7±5.7 43.5±3.5 37.5±4.0 0.339 
Collagen alpha-1(XVIII) P39061 182 37.2±3.7 38.0±2.4 36.5±5.3 0.829 
Collagen alpha-2(I) Q01149 130 3.0±2.6 3.9±1.0 3.9±0 0.929 
Collagen alpha-2(IV) P08122 167 1.2±2.1 2.0±3.4 1.6±2.8 >0.999 
Collagen alpha-2(VI) Q02788 110 35.6±3.4 47.1±5.9 47.5±6.3 0.071 
Collagen alpha-6(VI) Q8C6K9 246 18.2±2.2 30.2±4.7 34.9±5.2 0.025 
Decorin P28654 40 1.7±1.5 2.3±2.0 2.9±2.9 0.593 
Extracellular superoxide dismutase [Cu-Zn] O09164 27 38.5±11.3 43.5±6 44.3±2.4 0.829 
Fibromodulin P50608 43 0±0 2.0±3.4 1.9±1.9 0.679 
Fibronectin P11276 272 48.0±4.4 56.2±10.9 89.6±10.7 0.025 
Fibulin-2 P37889 132 1.6±2.8 1.6±2.8 7.4±7.7 0.071 
Fibulin-5 Q9WVH9 50 32.5±3.5 32.4±4.7 33.7±2.2 0.879 
Integrin alpha-5 P11688 115 0±0 0±0 1.0±1.7 >0.999 
Integrin alpha-IIb Q9QUM0 113 19.4±4.1 1.6±2.8 0±0 0.036 
Integrin beta-1 P09055 88 5.0±0.9 2.0±2.0 0.6±1.1 0.025 
Integrin beta-3 O54890 87 7.9±1.1 0.7±1.1 0±0 0.036 
Laminin subunit alpha-2 Q60675 343 1.8±3.1 4.9±1.7 6.5±2.1 0.132 
Laminin subunit alpha-4 P97927 202 1.4±2.5 3.6±3.1 2.6±2.2 0.529 
Laminin subunit beta-1 P02469 197 0.7±1.2 4.9±2.5 5.2±3.4 0.132 
Laminin subunit beta-2 Q61292 196 23.8±2.7 24.4±1.9 19.7±2.5 0.139 
Laminin subunit gamma-1 P02468 177 25.0±5.0 20.4±4.3 24.6±1.6 0.339 
Latent-TGFβ-binding protein 1 Q8CG19 187 1.7±1.5 1.0±1.7 4.9±1.0 0.068 
Latent-TGFβ-binding protein 4 Q8K4G1 179 120.8±21.
2 
123.7±10.1 130.9±17.7 0.629 
Lumican P51885 38 14.7±2.3 21.1±2.6 17.5±2.6 0.025 
Microfibril-associated glycoprotein 4 Q9D1H9 29 1.6±2.8 0±0 0±0 >0.999 
Mimecan Q62000 34 7.0±0.8 10.0±3.8 10.7±1.7 0.050 
Periostin Q62009 93 28.6±5.6 27.3±2.4 26.9±1.6 0.993 
Perlecan Q05793 398 126.5±13 131.5±1.1 129.4±7.2 0.721 
Prolargin Q9JK53 43 2.2±3.8 7.2±3.2 5.8±4.2 0.357 
Prolow-density lipoprotein receptor-
related protein 1 Q91ZX7 505 4.6±1.4 6.2±1.1 8.1±0.6 0.011 
Tenascin Q80YX1 232 1.1±1.8 2.9±1.0 1.3±2.3 0.400 
TGFβ-induced protein ig-h3 P82198 75 5.2±1.2 9.1±0.6 8.4±3.1 0.139 
Thrombospondin-1 P35441 130 17.5±2.9 13.6±1.9 7.4±3.7 0.011 
Versican Q62059 367 0±0 5.2±0.6 4.5±1.1 0.025 
vWF A domain-containing protein 5A Q99KC8 87 5.6±1.2 9.4±1.9 11±3.9 0.071 
 
Values are normalised Total Spectral counts (Av±SD). P-values for changes among the different groups (n=3) were identified by Kruskal-
Wallis test. Results in bold indicate P < 0.05. Values are average (Av) normalised total spectra ± standard deviation (SD). Control: 
incubation in buffer only. 
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Supplemental Table II.  ECM-related proteins in murine aortas of AngII-treated Adamts5+/+ and Adamts5Dcat mice. 
 
Identified proteins Uniprot accession 
Mr 
(kDa) 
Total 
spectra 
Unique 
spectra 
Unique 
peptides 
Sequence 
coverage  
Fold 
change 
P-
value 
Adiponectin  ADIPO 27 14 4 4 9.7 NA NA 
Aggrecan core protein  PGCA 222 328 54 34 17.0 1.10 0.662 
Agrin  AGRIN 208 87 21 19 10.6 1.15 0.792 
Alpha-2-HS-glycoprotein  FETUA 37 15 10 8 31.9 NA NA 
Amyloid beta A4 protein  A4 87 74 20 17 20.3 0.60 0.429 
Annexin A2  ANXA2 39 129 25 19 47.2 1.53 0.126 
Apolipoprotein A-I  APOA1 31 91 17 12 42.4 1.60 0.247 
Apolipoprotein A-IV  APOA4 45 31 10 10 19.2 1.35 0.794 
Apolipoprotein C-III  APOC3 11 7 5 3 50.5 NA NA 
Apolipoprotein E  APOE 36 56 19 13 43.4 3.32 0.420 
Asporin  ASPN 43 292 44 22 55.8 1.05 0.571 
Basal cell adhesion molecule  BCAM 68 157 30 23 35.7 0.69 0.082 
Beta-2-glycoprotein 1  APOH 39 118 23 17 60.6 2.06 0.082 
Biglycan  PGS1 42 845 90 31 66.9 1.05 0.792 
Cadherin-13  CAD13 78 43 6 6 9.5 1.20 0.662 
Cathepsin B  CATB 37 9 3 3 9.1 NA NA 
Cathepsin D  CATD 45 50 9 6 23.9 1.34 0.429 
Chondroitin sulfate proteoglycan 4  CSPG4 252 18 9 9 5.2 NA NA 
Chymase  CMA1 28 53 9 8 33.6 1.02 0.792 
Clusterin  CLUS 52 167 30 21 49.1 1.57 0.266 
Collagen alpha-1(I) chain  CO1A1 138 4768 269 114 76.0 0.87 0.355 
Collagen alpha-1(II) chain  CO2A1 142 125 13 10 10.1 0.93 0.662 
Collagen alpha-1(III) chain  CO3A1 139 756 114 62 52.8 0.54 0.931 
Collagen alpha-1(IV) chain  CO4A1 161 135 28 14 10.8 0.86 0.792 
Collagen alpha-1(V) chain  CO5A1 184 248 31 24 13.8 0.73 0.247 
Collagen alpha-1(VI) chain  CO6A1 108 247 53 35 33.4 0.66 0.178 
Collagen alpha-1(XI) chain  COBA1 181 25 7 6 4.2 NA NA 
Collagen alpha-1(XII) chain  COCA1 340 37 23 22 9.5 3.80 0.446 
Collagen alpha-1(XIII) chain  CODA1 73 2 2 2 8.7 NA NA 
Collagen alpha-1(XIV) chain  COEA1 193 55 19 18 8.9 1.13 0.922 
Collagen alpha-1(XV) chain  COFA1 140 162 25 17 14.9 1.08 0.931 
Collagen alpha-1(XVIII) chain  COIA1 182 427 56 35 23.7 0.94 0.537 
Collagen alpha-2(I) chain  CO1A2 130 2855 210 91 71.6 0.96 0.792 
Collagen alpha-2(IV) chain  CO4A2 167 80 19 14 9.0 0.83 0.792 
Collagen alpha-2(V) chain  CO5A2 145 457 62 43 41.3 1.33 0.178 
Collagen alpha-2(VI) chain  CO6A2 110 220 48 27 34.8 0.51 0.139 
Collagen alpha-3(IV) chain  CO4A3 162 2 2 2 1.9 NA NA 
Collagen alpha-6(VI) chain  CO6A6 246 65 20 20 10.6 0.26 0.121 
Connective tissue growth factor  CTGF 38 73 17 15 44.3 0.81 0.623 
Decorin  PGS2 40 721 84 34 73.2 1.21 0.126 
Dermatopontin  DERM 24 125 21 10 53.7 1.11 0.329 
Dystroglycan  DAG1 97 26 7 5 4.8 1.61 0.305 
Elastin  ELN 72 67 12 10 21.4 0.63 0.126 
EMILIN-1  EMIL1 108 21 9 9 5.2 0.86 0.794 
Extracellular matrix protein 1  ECM1 63 21 6 6 10.0 0.96 0.100 
Extracellular superoxide dismutase 
[Cu-Zn]  
SODE 27 268 40 16 74.1 1.04 0.931 
Fibrilli -1  FBN1 312 62 18 17 8.1 0.69 0.881 
Fibromodulin  FMOD 43 83 17 10 36.2 1.14 0.792 
Fibronectin  FINC 273 1424 244 124 58.6 1.00 0.792 
Fibulin-2  FBLN2 132 2 2 2 2.5 NA NA 
Fibulin-5  FBLN5 50 151 21 15 38.8 0.76 0.429 
Galectin-1  LEG1 15 121 17 9 48.1 1.38 0.056 
Galectin-3  LEG3 28 68 11 7 31.1 1.56 0.178 
Galectin-3-binding protein  LG3BP 64 5 5 5 14.2 NA NA 
Hyaluronan and proteoglycan link 
protein 1  
HPLN1 40 24 9 8 22.2 NA NA 
Kininogen-1  KNG1 73 4 4 4 11.5 NA NA 
Lactadherin  MFGM 51 372 53 27 60.9 1.03 >0.99 
Laminin subunit alpha-2  LAMA2 344 14 8 8 2.1 NA NA 
Laminin subunit alpha-4  LAMA4 202 83 18 18 9.6 1.09 0.931 
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Laminin subunit alpha-5  LAMA5 404 77 20 19 6.0 1.01 0.792 
Laminin subunit beta-1  LAMB1 197 5 5 5 2.5 NA NA 
Laminin subunit beta-2  LAMB2 197 224 46 37 20.0 1.06 0.792 
Laminin subunit gamma-1  LAMC1 177 201 41 35 20.8 1.03 0.931 
Latent-TGF β-binding protein 1  LTBP1 187 63 12 11 6.4 0.96 0.792 
Latent-TGF β-binding protein 2  LTBP2 196 16 7 7 4.6 NA NA 
Latent-TGF β-binding protein 4  LTBP4 179 247 49 37 21.6 0.86 0.537 
Lumican  LUM 38 575 66 28 72.8 1.38 0.056 
Matrix Gla protein  MGP 12 6 3 2 23.1 NA NA 
Metalloproteinase inhibitor 3  TIMP3 24 20 5 5 20.9 1.27 0.790 
Microfibril-associated glycoprotein 4  MFAP4 29 112 18 9 43.6 1.17 0.429 
Microfibrillar-associated protein 5  MFAP5 19 112 13 6 37.8 1.78 0.030 
Mimecan  MIME 34 494 54 27 58.7 1.26 0.247 
Nephronectin  NPNT 61 137 22 15 28.7 0.69 0.052 
Nidogen-1  NID1 137 285 54 41 32.4 1.12 0.329 
Nidogen-2  NID2 154 160 37 27 16.5 1.02 0.972 
Periostin  POSTN 93 503 94 53 51.3 0.75 0.429 
Perlecan PGBM 398 1810 271 148 46.4 0.91 0.537 
Prolargin  PRELP 43 455 51 26 77.8 1.33 0.178 
Prolow-density lipoprotein receptor-
related protein 1 
LRP1 505 28 13 12 2.55 NA NA 
Prosaposin  SAP 61 39 9 7 19.2 1.54 0.429 
Protein S100-A10  S10AA 11 38 7 5 52.6 2.30 0.080 
Protein S100-A11  S10AB 11 9 3 2 27.6 NA NA 
Protein S100-A4  S10A4 12 8 5 3 20.8 NA NA 
Sclerostin  SOST 23 27 5 4 18.0 0.73 0.329 
Serine protease HTRA1  HTRA1 51 308 41 24 49.2 0.79 0.792 
Serine protease HTRA3  HTRA3 49 35 12 10 20.9 1.09 >0.99 
SPARC  SPRC 34 17 5 5 12.6 0.65 0.550 
Tenascin  TENA 232 277 70 59 27.2 0.94 0.792 
TGF-β1  TGFB1 44 9 9 9 37.9 NA NA 
TGF-β2  TGFB2 48 19 4 3 12.1 2.10 0.268 
TGF-β3  TGFB3 47 4 2 2 6.1 NA NA 
TGF β-induced protein ig-h3  BGH3 75 91 24 18 31.0 0.66 0.429 
Thrombospondin type-1 domain-
containing protein 4  
THSD4 113 87 15 13 13.7 0.85 0.662 
Thrombospondin-1  TSP1 130 23 10 10 10.9 2.93 >0.99 
Tubulointerstitial nephritis antigen-like  TINAL 53 264 49 27 66.5 1.02 0.931 
Vascular cell adhesion protein 1  VCAM1 81 3 3 3 5.4 NA NA 
Versican CSPG2 367 112 20 14 4.6 2.19 0.009 
Vitronectin  VTNC 55 139 24 15 37.2 1.90 >0.99 
von Willebrand factor A domain-
containing protein 1  
VWA1 45 59 13 11 38.1 0.71 0.755 
 
Number of samples: WT n=6, KO: n=5 P values were derived from unpaired Mann Whitney tests and significant changes (p<0.05) are highlighted in 
bold. NA denotes "not applicable" (note that every time protein expression in more than 3 samples from both groups was undetectable, the test was not 
performed). Sequence coverage is given in %. 
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Supplemental Table III.  PRM parameter used for targeted MS analysis of unique peptides from versican. 
 
Versican 
Peptides Precursor m/z Precursor z 
Product 
ion 
Product ion 
m/z 
Retention 
time (min)  
LATVGELQAAWR 
(N-terminal) 
657.8619 2 y6 744.42 155.1 
  y7 873.46  
  y8 930.48  
  y9 1029.55  
  y10 1130.60  
  y11 1201.63  
YEINSLIR  
(C-terminal) 
504.2796 2 y3 401.29 118.1 
  y4 488.32  
  y5 602.36  
  y6 715.45  
   y7 844.49   
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Supplemental Figure I. Experimental design. Hypertension was induced by treating 10-week-old
Adamts5+/+ and Adamts5Δcat mice with AngII for 4 weeks. An ultrasound was performed before and
after 4 weeks of AngII infusion. Blood pressure measurements were acquired at 3 time points: 2
days before and 5 and 27 days after osmotic mini-pumps for AngII infusion were implanted.
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Supplemental Figure II
Supplemental Figure II. Quantification of versican (CSPG2) and TGF-b in the aortas of
AngII-treated Adamts5+/+ and Adamts5Dcat mice by densitometry. Bars represent mean±SD.
Statistical significance was calculated using unpaired Student’s t-test. * denotes P<0.05
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Supplemental Figure III
Supplemental Figure III. Gene expression in murine aortas. Relative gene expression of
Adamts1, 4 and 5, Tgfb1, 2 and 3 and Tgfbr1, 2 and 3 in aortas from untreated Adamts5+/+
(n=6) and Adamts5Δcat (n=5) mice. β-actin was used as reference gene. Data points are
means±SD. Black squares denote P<0.05 as determined by Mann-Whitney tests.
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Supplemental Figure IV. LRP1 in mouse aortas. Quantification of LRP1 in aortas of untreated
and AngII-treated Adamts5+/+ and Adamts5Δcat mice by densitometry. Bars represent means±SD.
The intensity values in Adamts5+/+ aortas served as reference. Statistical significance was
calculated using unpaired Student’s t-test. ** denotes P<0.01.
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Supplemental Figure V. LRP1 siRNA, protein expression. Quantification of LRP1, the N-
terminal fragment of versican (versikine) and the two forms of ADAMTS1 by densitometry. SMCs
transfected with scrambled siRNA served as reference. Bars represent mean±SD. Statistical
significance was calculated using one-way ANOVA with Dunnett’s post hoc test. * denotes
P<0.05, ** P<0.01, *** P<0.001.
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